Aposense® (formerly NST) is a clinical stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo.
Aposense® is translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple disease categories, including oncology, cardiology and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.
Our product pipeline is based on our patented Aposense® platform technology, comprising a set of rationally-designed, small molecules with the demonstrated ability to identify and accumulate within apoptotic cells, in vivo.
Our clinical technological expertise draws on more than 120 collective years of research and development in the field of apoptosis. Our multidisciplinary team of scientists combines talent in chemistry, medicine, cell biology, pre-clinical experimental models and rational drug design.